Recruiting

DRP® Method

Sponsor:

Allarity Therapeutics

Code:

NCT03877796

Conditions

Ovarian Cancer

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Drug Response Predictor® (DRP)

Study Details

Brief summary:

The patient's local archival tumor tissue (FFPE) from original tumor, or from the metastatic tissue, will be collected to potentially identify if they - at a later stage of their disease - will be likely to benefit from treatment with any of the investigational cancer drugs available to Allarity Therapeutics. Data from this study can further be used to explore in a retrospective fashion, sensitivity to other chemotherapeutic drugs previously used in the treatment of their ovarian cancer, to investigate whether or not the DRP® method can predict and confirm the obtained sensitivity to the prior given drugs as well as prospective analyses guiding the Investigators on future treatments.

Conditions

Ovarian Cancer

Study ID

NCT03877796

Start date

Apr 11, 2019

Status verified date

Jul, 2026

Completion date

Dec, 2027

Anticipated

Primary completion date

Jun, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Patients with histological confirmed epithelia ovarian cancer
  • Patients must have platinum-resistant disease, defined as progression within 6 months after the last dose of platinum-based chemotherapy, or are platinum ineligible.
  • Patients have received no more than one prior line of therapy in the platinum resistant or platinum ineligible setting
  • FFPE tumor tissue available

Exclusion Criteria:

  • Patients who have platinum-refractory disease, defined as progression during the last platinum-based chemotherapy.
  • Other malignancy with exception of any stage I and II cancer that is deemed cured by the Investigator

Study Design

Enrollment

60 participants

Anticipated

Interventions and Outcome Measures

Arms

Ovarian cancer patients

with formalin-fixed paraffin-embedded (FFPE) tumor tissue available

Interventions

Drug Response Predictor® (DRP)

A DRP is an assay that based on samples from a tumor can predict whether the tumor will respond to a specific drug or not.

Primary outcome measure

  • Identification of ovarian cancer patients with high likelihood of being sensitive to investigational cancer drug [ Time Frame: up to 2 years ]

Central Contacts and Locations

Central contacts

US: Kathleen Moore

+1 405-271-8707KathleenMoore@ouhealth.com

Europe: Rebecca Kristeleit

Rebecca.Kristeleit@gstt.nhs.uk

Locations

Moffitt Cancer Center

Recruiting

Tampa, Florida, United States, 33612

Emory Winship Cancer Institute

Recruiting

Atlanta, Georgia, United States, 30322

Contacts

Nilaab Meer

494-778-1900nilaab.meer@emory.edu

Principal Investigator:

Jennifer Scalici, MD

University of New Mexico Comprehensive Cancer

Recruiting

Albuquerque, New Mexico, United States, 87131

Contacts

Natalie Everett

nseverett@salud.unm.edu

Principal Investigator:

Amaranta Craig, MD

The Blavatnik Family-Chelsea Medical Center at Mount Sinai

Recruiting

New York, New York, United States, 10011

Contacts

Neha Kumarley

212-824-7859neha.kumarley@mssm.edu

Principal Investigator:

Stephanie Blank, MD

OU Health Stephenson Cancer Center

Recruiting

Oklahoma City, Oklahoma, United States, 73104

Contacts

Christine Pappaterra, RN

405-271-8707Christine-Pappaterra@ouhsc.edu

Principal Investigator:

Jacqueline Bohn,, MD

University Medical Center Cancer Center

Recruiting

Lubbock, Texas, United States, 79415

Contacts

Mariana Fiori

Mariana.Fiori@ttuhsc.edu

Principal Investigator:

Mark Reedy, MD

Swedish Center for Research and Innovation

Recruiting

Seattle, Washington, United States, 98122

Contacts

Karina Sills

206-386-2227karina.sills@swedish.org

Principal Investigator:

Fernanda Baptista Musa, MD

More Information

Sponsor

Allarity Therapeutics

Last update posted

Jul 30, 2026

Last verified

Jul, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Allarity Therapeutics on 2026-07-30.